Palliative care resources for the holiday period

November 30, 2025

In the lead up to the holiday period, supporting patients and carers in palliative care is crucial.

The Palliative Care Access to Core Medicines project aims to support palliative care in the community and assists people who wish to die at home through timely access to essential medicines. This minimises suffering associated with emergent end-of-life symptoms. 

For Clinics: The SEMPHN webpage has a map of pharmacists in your area who stock medications often used at end-of-life:  Over 100 pharmacies in the south-east region of Melbourne have committed to stocking these medications, making access to medications easier for your patients. 

For Pharmacists: Pharmacists who wish to join the list can fill out the Letter of Intent. Pharmacists can also access a free online training program created by the Pharmaceutical Society of Australia. The ASPIRE program was developed to upskill pharmacists with the foundation knowledge and skills needed to provide palliative care support to their patients through quality use of medicines.

The Victorian Palliative Care Advice Service (PCAS) is for everyone everywhere in Victoria, and can also help to support patients and carers over the holiday period. PCAS offers free, confidential advice for all Victorians seeking information about life-limiting illness, palliative care or end-of-life care. If you are a doctor, nurse, healthcare worker or provider we can assist with symptom management, prescribing and decision-making.


Latest news

May 4, 2026
New community resource kit providing ready-to-share information on the recent changes to bulk billing and how to find your nearest bulk billing practice.
May 4, 2026
New statewide referral criteria for 12 children’s orthopaedics conditions came into effect on 20 April 2026 in all Victorian public hospitals. The children’s orthopaedics suite joins 20 suites of specialist referral criteria already in existence across Victoria.
April 29, 2026
A statewide investigation has found no evidence of an increased risk of giant cell arteritis (GCA) following COVID-19 vaccination, providing reassurance for clinicians counselling patients about vaccine safety.